FDA Exempts Phase I Drugs From GMPs, Issues Guidance for INDs

Washington Drug Letter
More than two years after withdrawing a final rule that would have exempted investigational drugs in Phase I testing from certain good manufacturing practice (GMP) regulations, the FDA is issuing a final rule to do just that.

To View This Article:


Buy This Article Now

Add this article to your cart for $10.00